<DOC>
	<DOCNO>NCT00018161</DOCNO>
	<brief_summary>This protocol evaluate efficacy combine pharmacologic treatment smoke cessation , entail use nicotine skin patch nicotinic antagonist mecamylamine , specific behavioral therapy design inhibit smoke urge .</brief_summary>
	<brief_title>Treatment Quit Smoking</brief_title>
	<detailed_description>Previous study find nicotine/mecamylamine treatment double long-term abstinence rate relative nicotine replacement alone . Recent evidence support hypothesis nicotine/mecamylamine treatment prior smoke cessation partially block reward effect cigarette smoke hence promotes extinction smoke habit , facilitate subsequent abstinence . The behavioral approach employ also extinction strategy involve smoker switch de-nicotinized tobacco cigarette two week prior quit smoke . It hypothesize use de-nicotinized cigarette might provide complete extinction provide partial pharmacologic blockade use nicotine/mecamylamine alone . The pharmacologic treatment expect increase compliance de-nicotinized cigarette smoke regimen , subject ' usual brand cigarettes less appeal absence nicotine/mecamylamine treatment . Together brand-switching nicotine/mecamylamine therapy expect reduce craving withdrawal symptom well increase long-term abstinence smoking .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Mecamylamine</mesh_term>
	<criteria>Smokers , Ages 1865 , want quit smoking . Must good health Exclude cardiac disease , hypotensive hypertensive , skin allergy , glaucoma , prostatic hypertrophy , pregnant woman , drug alcohol abuse , kidney disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Nicotine</keyword>
	<keyword>addiction</keyword>
	<keyword>cigarette smoking</keyword>
</DOC>